aspirin has been researched along with Adenomatous Polyposis Coli, Familial in 62 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To describe the role of celecoxib as adjunctive therapy in the treatment of familial adenomatous polyposis (FAP), an inherited autosomal dominant predisposition syndrome for colorectal cancer." | 8.81 | Celecoxib as adjunctive therapy for treatment of colorectal cancer. ( North, GL, 2001) |
| "There is increasing evidence to suggest that aspirin and other non-steroidal anti-inflammatory drugs reduce the risk of colorectal cancer." | 8.80 | Non-steroidal anti-inflammatory drugs and selective apoptotic anti-neoplastic drugs in the prevention of colorectal cancer: the role of super aspirins. ( Arber, N; Strul, H, 2000) |
| "We tested these hypotheses among participants in the Aspirin/Folate Polyp Prevention Study who were randomly assigned to placebo or to aspirin treatment (81 or 325 mg daily) and followed for 3 years for the occurrence of new adenomas." | 7.73 | Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. ( Ahnen, DJ; Baron, JA; Barry, EL; Bhat, S; Burke, CA; Grau, MV; Haile, RW; O'Brien, TG; Sandler, RS, 2006) |
| "Nine trials with 150 familial adenomatous polyposis (FAP) and 24,143 population subjects met the inclusion criteria." | 6.42 | Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. ( Asano, TK; McLeod, RS, 2004) |
| "Selective killing of tetraploid cells was observed for a series of additional agents that indirectly or directly stimulate AMP-activated protein kinase (AMPK) including salicylate, whose chemopreventive action has been established by epidemiological studies and clinical trials." | 5.40 | Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. ( Boilève, A; Bordenave, C; Castedo, M; Garcia, P; Jemaà, M; Kepp, O; Kroemer, G; Lissa, D; Michaud, M; Michels, J; Obrist, F; Pietrocola, F; Rello-Varona, S; Senovilla, L; Vitale, I, 2014) |
| "The strongest evidence is for non-steroidal anti-inflammatory drugs slowing polyp progression, notably Sulindac and aspirin in patients with familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer, respectively." | 4.95 | Chemoprevention of colorectal neoplasia. ( Eglinton, T; Eteuati, J; Frizelle, F; Hollington, P; Keenan, J; Wakeman, C, 2017) |
| "Prolonged use of aspirin and/or non-steroidal anti-inflammatory drugs induces a partial regression of either sporadic adenomas or adenomas in adenomatous polyposis coli (APC), but also their emergence and colonic cancer development in sporadic adenomas." | 4.82 | [Cyclooxygenase 2 inhibitors and adenomatous polyposis coli]. ( Florent, C; Meary, N, 2004) |
| "Prolonged use of aspirin and\\or non-steroidal anti-inflammatory drugs induces a partial regression of either sporadic adenomas or adenomas in adenomatous polyposis coli (APC), but also their emergence and colonic cancer development in sporadic adenomas." | 4.82 | [Cyclooxygenase 2 inhibitors and adenomatous polyposis coli]. ( Florent, C; Meary, N, 2004) |
| "To describe the role of celecoxib as adjunctive therapy in the treatment of familial adenomatous polyposis (FAP), an inherited autosomal dominant predisposition syndrome for colorectal cancer." | 4.81 | Celecoxib as adjunctive therapy for treatment of colorectal cancer. ( North, GL, 2001) |
| "Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced risk of colorectal cancer." | 4.80 | Nonsteroidal anti-inflammatory drugs, COX-2 and colorectal cancer. ( Patrignani, P, 2000) |
| "There is increasing evidence to suggest that aspirin and other non-steroidal anti-inflammatory drugs reduce the risk of colorectal cancer." | 4.80 | Non-steroidal anti-inflammatory drugs and selective apoptotic anti-neoplastic drugs in the prevention of colorectal cancer: the role of super aspirins. ( Arber, N; Strul, H, 2000) |
| "In rodents, nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin inhibit chemically induced adenomas and early carcinomas of the colon." | 4.79 | Aspirin and gastrointestinal cancer. ( Thun, MJ, 1997) |
| "We tested these hypotheses among participants in the Aspirin/Folate Polyp Prevention Study who were randomly assigned to placebo or to aspirin treatment (81 or 325 mg daily) and followed for 3 years for the occurrence of new adenomas." | 3.73 | Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. ( Ahnen, DJ; Baron, JA; Barry, EL; Bhat, S; Burke, CA; Grau, MV; Haile, RW; O'Brien, TG; Sandler, RS, 2006) |
| "The Apc1638N mouse model, which carries a targeted mutant allele within the adenomatous polyposis (Apc) gene and develops intestinal tumours spontaneously, predominantly in the small bowel, was used to investigate the effects of two potential chemopreventive agents, aspirin and alpha-amylase resistant starch (RS)." | 3.70 | Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. ( Burn, J; Coaker, J; Fodde, R; Kartheuser, A; Kooshkghazi, MD; Mathers, JC; Williamson, SL, 1999) |
| "Side effects, such as arrhythmia, angina pectoris, and nervous headache, were observed in the celecoxib 400 mg/d group." | 2.72 | [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis]. ( Geng, HG; Li, SR; Sheng, JQ; Su, H; Yan, W; Yang, XY; Yu, DL; Zhang, YH, 2006) |
| "In CAPP2, 1009 Lynch syndrome gene carriers were recruited from 43 international centres." | 2.49 | Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC). ( Bishop, DT; Burn, J; Mathers, J, 2013) |
| "Loss of function of the adenomatous polyposis coli (APC) tumour suppressor gene through truncating mutations or other means is an early event in most colo-rectal cancer (CRC)." | 2.42 | Can resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 Study. ( Bishop, DT; Burn, J; Chapman, PC; Mathers, JC; Mickleburgh, I, 2003) |
| "Nine trials with 150 familial adenomatous polyposis (FAP) and 24,143 population subjects met the inclusion criteria." | 2.42 | Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. ( Asano, TK; McLeod, RS, 2004) |
| " Chemoprevention of colorectal cancer that involves the long-term use of pharmacological agents as aspirin also seems to be effective." | 2.42 | Is colorectal cancer an avoidable disease nowadays? ( Benamouzig, R, 2004) |
| " Many epidemiologic studies have found that long-term use of NSAIDs is associated with a lower risk of colorectal cancer, adenomatous polyps, and, to some extent, other cancers." | 2.41 | Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. ( Henley, SJ; Patrono, C; Thun, MJ, 2002) |
| "Gastrointestinal cancers are among the leading sites of cancer and leading causes of cancer-related deaths." | 2.39 | Prevention of gastrointestinal cancer--the potential role of NSAIDs in colorectal cancer. ( Luk, GD, 1996) |
| "Selective killing of tetraploid cells was observed for a series of additional agents that indirectly or directly stimulate AMP-activated protein kinase (AMPK) including salicylate, whose chemopreventive action has been established by epidemiological studies and clinical trials." | 1.40 | Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. ( Boilève, A; Bordenave, C; Castedo, M; Garcia, P; Jemaà, M; Kepp, O; Kroemer, G; Lissa, D; Michaud, M; Michels, J; Obrist, F; Pietrocola, F; Rello-Varona, S; Senovilla, L; Vitale, I, 2014) |
| "The rapidly increasing incidence of colorectal cancer in Japan poses a great challenge to researchers to develop preventive strategies against this disease." | 1.35 | Chemoprevention of colorectal cancer in Japan: a brief introduction to current clinical trials. ( Gondo, N; Ishikawa, H; Kawano, A; Nakamura, T; Sakai, T, 2009) |
| "We investigated adenomatous polyposis coli gene mutations in six unrelated families with familial adenomatous polyposis by using heteroduplex analysis and DNA sequencing." | 1.34 | The mutation spectrum of the APC gene in Turkish patients with familial adenomatous polyposis. ( Cecener, G; Egeli, U; Tunca, B; Yilmazlar, T; Zorluoglu, A, 2007) |
| "Aspirin was found to have no effect on tumour number and size when administered to Min/+ mice with established polyposis." | 1.31 | Therapeutic utility of aspirin in the ApcMin/+ murine model of colon carcinogenesis. ( Miller, MJ; Reuter, BK; Zhang, XJ, 2002) |
| "Aspirin (400 ppm) has a similar impact on reducing prostaglandin levels, but in contrast to indomethacin, is uneffective in reducing the tumor load." | 1.31 | Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+)mice. ( Chiu, CH; McEntee, MF; Whelan, J, 2000) |
| "Mutation of the adenomatous polyposis coli (APC) gene and the subsequent dysregulation of beta-catenin are well-documented abnormalities in familial adenomatous polyposis (FAP), as well as sporadic polyposis." | 1.31 | Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. ( Dedhar, S; Dupuis, B; Gallinger, S; Gray, V; Malik, S; Marotta, A; Owen, D; Salh, B; Sanghera, J; Tan, C, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (19.35) | 18.2507 |
| 2000's | 28 (45.16) | 29.6817 |
| 2010's | 16 (25.81) | 24.3611 |
| 2020's | 6 (9.68) | 2.80 |
| Authors | Studies |
|---|---|
| Monahan, KJ | 1 |
| Swinyard, O | 1 |
| Latchford, A | 1 |
| Saito, E | 1 |
| Mutoh, M | 3 |
| Ishikawa, H | 5 |
| Kamo, K | 1 |
| Fukui, K | 1 |
| Hori, M | 1 |
| Ito, Y | 1 |
| Chen, Y | 1 |
| Sigel, B | 1 |
| Sekiguchi, M | 1 |
| Hemmi, O | 1 |
| Katanoda, K | 1 |
| Kemp Bohan, PM | 1 |
| Mankaney, G | 1 |
| Vreeland, TJ | 1 |
| Chick, RC | 1 |
| Hale, DF | 1 |
| Cindass, JL | 1 |
| Hickerson, AT | 1 |
| Ensley, DC | 1 |
| Sohn, V | 1 |
| Clifton, GT | 1 |
| Peoples, GE | 1 |
| Burke, CA | 3 |
| Dunbar, K | 1 |
| Valanciute, A | 1 |
| Lima, ACS | 1 |
| Vinuela, PF | 1 |
| Jamieson, T | 1 |
| Rajasekaran, V | 1 |
| Blackmur, J | 1 |
| Ochocka-Fox, AM | 1 |
| Guazzelli, A | 1 |
| Cammareri, P | 1 |
| Arends, MJ | 1 |
| Sansom, OJ | 1 |
| Myant, KB | 1 |
| Farrington, SM | 1 |
| Dunlop, MG | 3 |
| Din, FVN | 1 |
| Sato, Y | 1 |
| Doyama, H | 1 |
| Tajika, M | 1 |
| Tanaka, S | 1 |
| Horimatsu, T | 1 |
| Takeuchi, Y | 1 |
| Kashida, H | 1 |
| Tashiro, J | 1 |
| Ezoe, Y | 1 |
| Nakajima, T | 1 |
| Ikematsu, H | 1 |
| Hori, S | 1 |
| Suzuki, S | 2 |
| Otani, T | 1 |
| Takayama, T | 1 |
| Ohda, Y | 1 |
| Mure, K | 1 |
| Wakabayashi, K | 2 |
| Sakai, T | 3 |
| Lynch, PM | 3 |
| Hirata, K | 1 |
| Nakamura, T | 2 |
| Takeyama, I | 1 |
| Kawano, A | 2 |
| Gondo, N | 2 |
| Abe, T | 1 |
| Tokudome, S | 1 |
| Goto, C | 1 |
| Matsuura, N | 1 |
| Lissa, D | 1 |
| Senovilla, L | 1 |
| Rello-Varona, S | 1 |
| Vitale, I | 1 |
| Michaud, M | 1 |
| Pietrocola, F | 1 |
| Boilève, A | 1 |
| Obrist, F | 1 |
| Bordenave, C | 1 |
| Garcia, P | 1 |
| Michels, J | 1 |
| Jemaà, M | 1 |
| Kepp, O | 1 |
| Castedo, M | 1 |
| Kroemer, G | 1 |
| Errico, A | 1 |
| Wang, R | 1 |
| Wang, Y | 1 |
| Gao, Z | 1 |
| Qu, X | 1 |
| Wakeman, C | 1 |
| Keenan, J | 1 |
| Eteuati, J | 1 |
| Hollington, P | 1 |
| Eglinton, T | 1 |
| Frizelle, F | 1 |
| Walcott, FL | 1 |
| Patel, J | 1 |
| Lubet, R | 1 |
| Rodriguez, L | 1 |
| Calzone, KA | 1 |
| Ricciardiello, L | 1 |
| Ahnen, DJ | 2 |
| Robb-Nicholson, C | 1 |
| Arber, N | 3 |
| Spicak, J | 1 |
| Rácz, I | 1 |
| Zavoral, M | 1 |
| Breazna, A | 1 |
| Gerletti, P | 1 |
| Lechuga, MJ | 1 |
| Collins, N | 1 |
| Rosenstein, RB | 1 |
| Eagle, CJ | 1 |
| Levin, B | 1 |
| Chan, AT | 2 |
| Burn, J | 5 |
| Bishop, DT | 3 |
| Chapman, PD | 2 |
| Elliott, F | 1 |
| Bertario, L | 1 |
| Eccles, D | 1 |
| Ellis, A | 1 |
| Evans, DG | 1 |
| Fodde, R | 2 |
| Maher, ER | 1 |
| Möslein, G | 1 |
| Vasen, HF | 1 |
| Coaker, J | 2 |
| Phillips, RK | 1 |
| Bülow, S | 1 |
| Mathers, JC | 3 |
| Ferrández, A | 1 |
| Piazuelo, E | 1 |
| Castells, A | 1 |
| Manzano, A | 1 |
| Pérez-Segura, P | 1 |
| Mathers, J | 1 |
| Reuter, BK | 1 |
| Zhang, XJ | 1 |
| Miller, MJ | 1 |
| Bauer, WM | 1 |
| Lashner, B | 1 |
| Mickleburgh, I | 1 |
| Chapman, PC | 1 |
| Schmiegel, W | 2 |
| Reinacher-Schick, A | 1 |
| Asano, TK | 1 |
| McLeod, RS | 1 |
| Herszényi, L | 1 |
| Juhász, M | 1 |
| Prónai, L | 1 |
| Tulassay, Z | 1 |
| Din, FV | 1 |
| Stark, LA | 1 |
| Florent, C | 2 |
| Meary, N | 2 |
| Pox, C | 1 |
| Kroesen, A | 1 |
| Benamouzig, R | 2 |
| Raskov, HH | 1 |
| Sheng, JQ | 1 |
| Li, SR | 1 |
| Yang, XY | 1 |
| Zhang, YH | 1 |
| Su, H | 1 |
| Yu, DL | 1 |
| Yan, W | 1 |
| Geng, HG | 1 |
| Barry, EL | 1 |
| Baron, JA | 1 |
| Bhat, S | 1 |
| Grau, MV | 1 |
| Sandler, RS | 3 |
| Haile, RW | 1 |
| O'Brien, TG | 1 |
| Tunca, B | 1 |
| Cecener, G | 1 |
| Egeli, U | 1 |
| Zorluoglu, A | 1 |
| Yilmazlar, T | 1 |
| Robles-Díaz, G | 1 |
| Fastag, D | 1 |
| Thun, MJ | 3 |
| Eisen, GM | 1 |
| Wurzelmann, JI | 1 |
| Ransohoff, DF | 1 |
| Talal, A | 1 |
| Eastham, EJ | 1 |
| Luk, GD | 1 |
| DuBois, RN | 1 |
| Giardiello, FM | 1 |
| Smalley, WE | 1 |
| Levy, GN | 1 |
| Barnes, CJ | 1 |
| Lee, M | 1 |
| Mahmoud, NN | 1 |
| Dannenberg, AJ | 1 |
| Mestre, J | 1 |
| Bilinski, RT | 1 |
| Churchill, MR | 1 |
| Martucci, C | 1 |
| Newmark, H | 1 |
| Bertagnolli, MM | 1 |
| Seidensticker, F | 1 |
| Schmiegel, WH | 1 |
| Williamson, SL | 1 |
| Kartheuser, A | 1 |
| Kooshkghazi, MD | 1 |
| Lamberti, C | 1 |
| Jungck, M | 1 |
| Caspari, R | 1 |
| Schmidt-Wolf, I | 1 |
| Sauerbruch, T | 1 |
| Patrignani, P | 1 |
| Chiu, CH | 1 |
| McEntee, MF | 1 |
| Whelan, J | 1 |
| Strul, H | 1 |
| Marotta, A | 1 |
| Tan, C | 1 |
| Gray, V | 1 |
| Malik, S | 1 |
| Gallinger, S | 1 |
| Sanghera, J | 1 |
| Dupuis, B | 1 |
| Owen, D | 1 |
| Dedhar, S | 1 |
| Salh, B | 1 |
| North, GL | 1 |
| Henley, SJ | 1 |
| Patrono, C | 1 |
| Chaussade, S | 1 |
| Ota, S | 1 |
| Bamba, H | 1 |
| Imai, Y | 1 |
| Arai, S | 1 |
| Fujiwara, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)[NCT00141193] | Phase 3 | 1,561 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| Comparison Study of a Low-Fat Diet Supplemented With Fish Oil and a Standard Western Diet in Individuals With Prostate Cancer[NCT00798876] | 56 participants (Actual) | Interventional | 2001-12-18 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
33 reviews available for aspirin and Adenomatous Polyposis Coli, Familial
| Article | Year |
|---|---|
Biology of Precancers and Opportunities for Cancer Interception: Lesson from Colorectal Cancer Susceptibility Syndromes.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biology; Colorectal Ne | 2023 |
Chemoprevention in familial adenomatous polyposis: past, present and future.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; As | 2021 |
Chemoprevention of colorectal neoplasia.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, No | 2017 |
Hereditary cancer syndromes as model systems for chemopreventive agent development.
Topics: Adaptor Proteins, Signal Transducing; Adenomatous Polyposis Coli; Adenosine Triphosphatases; Animals | 2016 |
Chemoprevention of familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; | 2016 |
Chemoprevention of hereditary colon cancers: time for new strategies.
Topics: Adenomatous Polyposis Coli; Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy P | 2016 |
Aspirin and the prevention of colorectal cancer.
Topics: Adenoma; Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Ne | 2012 |
Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?
Topics: Adenoma; Adenomatous Polyposis Coli; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspiri | 2012 |
Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC).
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aspirin; Child; Colorectal Neoplasms, Hereditary Nonp | 2013 |
Chemoprevention of colorectal cancer: slow, steady progress.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; | 2003 |
Can resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 Study.
Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Aspirin; Colonic Neoplasms; Colorect | 2003 |
Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future challenges in chemoprevention.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Color | 2003 |
Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas.
Topics: Adenoma; Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Co | 2004 |
[Chemoprevention of colorectal cancer].
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agent | 2004 |
[Cyclooxygenase 2 inhibitors and adenomatous polyposis coli].
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 2004 |
Is colorectal cancer an avoidable disease nowadays?
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; | 2004 |
[Cyclooxygenase 2 inhibitors and adenomatous polyposis coli].
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; | 2004 |
[Non-steroidal anti-inflammatory agents and prevention of colorectal adenomas and carcinomas].
Topics: Adenoma; Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2006 |
[Cancer of the pancreas. Epidemiology and risk factors].
Topics: Adenomatous Polyposis Coli; Age Factors; Aged; Aspirin; Breast Neoplasms; Diabetes Mellitus, Type 2; | 2007 |
Aspirin, NSAIDs, and digestive tract cancers.
Topics: Adenomatous Polyposis Coli; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic | 1994 |
Prevention of gastrointestinal cancer--the potential role of NSAIDs in colorectal cancer.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 1996 |
Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer.
Topics: Adenocarcinoma; Adenoma; Adenomatous Polyposis Coli; Adult; Animals; Anti-Inflammatory Agents, Non-S | 1996 |
Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agent | 1996 |
Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Arachido | 1997 |
Aspirin and gastrointestinal cancer.
Topics: Adenoma; Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinoge | 1997 |
[Practice-relevant intestinal diseases: prevention of colon carcinoma].
Topics: Adenomatous Polyposis Coli; Aspirin; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyp | 1998 |
Nonsteroidal anti-inflammatory drugs, COX-2 and colorectal cancer.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Ne | 2000 |
Do NSAIDs prevent colorectal cancer?
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neopl | 2000 |
Non-steroidal anti-inflammatory drugs and selective apoptotic anti-neoplastic drugs in the prevention of colorectal cancer: the role of super aspirins.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2000 |
Celecoxib as adjunctive therapy for treatment of colorectal cancer.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Chemotherap | 2001 |
Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.
Topics: Adenomatous Polyposis Coli; Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroida | 2002 |
[Chemoprevention of colorectal cancer].
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2002 |
[Colon cancer and COX-2].
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neopl | 2002 |
6 trials available for aspirin and Adenomatous Polyposis Coli, Familial
| Article | Year |
|---|---|
Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control St | 2021 |
Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial.
Topics: Adenoma; Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogeni | 2013 |
Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial.
Topics: Adenomatous Polyposis Coli; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Aspirin; Col | 2011 |
A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chi | 2011 |
[Acetylsalicylic acid for prevention of colorectal adenomas. The APP Study].
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonoscopy; Colorecta | 2003 |
[Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Angina Pectoris; Anti-Inflammatory Agents, Non- | 2006 |
23 other studies available for aspirin and Adenomatous Polyposis Coli, Familial
| Article | Year |
|---|---|
Cost-effectiveness of preventive aspirin use and intensive downstaging polypectomy in patients with familial adenomatous polyposis: A microsimulation modeling study.
Topics: Adenomatous Polyposis Coli; Aspirin; Cost-Benefit Analysis; Humans; Japan; Proctocolectomy, Restorat | 2023 |
Aspirin Rescues Wnt-Driven Stem-like Phenotype in Human Intestinal Organoids and Increases the Wnt Antagonist Dickkopf-1.
Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Aspirin; Disease Models, An | 2021 |
Low-dose aspirin and mesalazine for patients with familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Aspirin; Chemoprevention; Colectomy; Double-Blind Method; Humans; Mesala | 2021 |
Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention.
Topics: Adenomatous Polyposis Coli; Animals; Aspirin; Cell Death; Cell Line, Tumor; Epithelial Cells; Flow C | 2014 |
Prevention: daily aspirin and chemoprevention.
Topics: Acetaminophen; Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticar | 2014 |
The comparative study of acetyl-11-keto-beta-boswellic acid (AKBA) and aspirin in the prevention of intestinal adenomatous polyposis in APC(Min/+) mice.
Topics: Adenocarcinoma; Adenomatous Polyposis Coli; Administration, Oral; Animals; Anti-Inflammatory Agents; | 2014 |
Colorectal cancer prevention of familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Aspirin; Chemoprevention; Colonoscopy; Colorectal Neoplasms; Humans | 2016 |
Chemoprevention of colorectal cancer in Japan: a brief introduction to current clinical trials.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Color | 2009 |
By the way, doctor. I keep hearing that aspirin can help prevent colon cancer, but I have no idea how much I should take. Can you help? I've had adenomatous polyps in the past.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspiri | 2010 |
Aspirin and familial adenomatous polyposis: coming full circle.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans | 2011 |
Therapeutic utility of aspirin in the ApcMin/+ murine model of colon carcinogenesis.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2002 |
Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis.
Topics: Adenomatous Polyposis Coli; Apoptosis; Aspirin; beta Catenin; Breast Neoplasms; Cell Nucleus; Colore | 2004 |
[Ulcerative colitis. Cancer prevention].
Topics: Adenoma; Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy | 2004 |
Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention.
Topics: Adenoma; Adenomatous Polyposis Coli; Aged; Alanine; Anticarcinogenic Agents; Aspirin; Colorectal Neo | 2006 |
The mutation spectrum of the APC gene in Turkish patients with familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Aspirin; Biomarkers, Tumor; Caffeine; Diazepam; Dihydroergotamine; Drug | 2007 |
Evaluating risk: a primer for gastroenterologists.
Topics: Adenomatous Polyposis Coli; Aspirin; Colorectal Neoplasms; Duodenal Neoplasms; Humans; Intestinal Ne | 1995 |
Familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Aspirin; Child; Clinical Trials as T | 1994 |
Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin.
Topics: Adenoma; Adenomatous Polyposis Coli; Animals; Aspirin; Diet; Dinoprostone; Dose-Response Relationshi | 1998 |
Aspirin prevents tumors in a murine model of familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; be | 1998 |
Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months.
Topics: Adenocarcinoma; Adenoma; Adenomatous Polyposis Coli; Adipose Tissue; alpha-Amylases; Animals; Anti-I | 1999 |
[Therapy and after-care of familial adenomatous polyposis and hereditary colorectal carcinoma without polyposis].
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aftercare; Anti-Inflammatory Agents, Non-Steroidal; A | 2000 |
Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+)mice.
Topics: 6-Ketoprostaglandin F1 alpha; Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Ste | 2000 |
Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Diseas | 2001 |